VXL — Vaxil Bio Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$2.05m
- CA$1.05m
- 34
- 20
- 40
- 22
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.05 | -1.15 | -1.36 | -0.986 | -0.584 |
Depreciation | |||||
Non-Cash Items | 0.097 | 0.151 | 0.161 | 0.07 | 0.017 |
Other Non-Cash Items | |||||
Changes in Working Capital | -0.049 | 0.307 | 0.037 | -0.193 | -0.169 |
Change in Accounts Receivable | |||||
Change in Accounts Payable | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -0.943 | -0.596 | -1.1 | -1.08 | -0.734 |
Financing Cash Flow Items | 0 | — | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.52 | -0.068 | 2.56 | 1.81 | 0 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.584 | -0.67 | 1.43 | 0.731 | -0.731 |